Hidetoshi Hayashi
Expertise in
8
conditions

Hidetoshi Hayashi

Sakai, JP 
Expertise in
8
conditions
Sakai, JP 

Overview

Hidetoshi Hayashi practices practicing medicine in Sakai, Japan.

Hayashi is highly rated in 8 conditions, according to our data. Their clinical expertise encompasses Non-Small Cell Lung Cancer (NSCLC), EGFR Positive Lung Cancer, Lung Cancer, Pancreaticoduodenectomy, and Tissue Biopsy.

They are actively involved in clinical research, co-authoring 382 peer reviewed articles and participating in 6 clinical trials.

Locations

Sakai, Japan
Other Locations
Nagoya, 4678603, Japan
Sakai, 5900197, Japan
Osaka, Japan
Tokyo, Japan
Komaki, Japan
Sayama, Japan
Oyamadai, Japan
Sayama, Japan
Tochigi, Japan
Ebetsu, Japan
Setagaya, 1580082, Japan
Kumamoto, Japan
Higashi-osaka, 5778502, Japan
Tsuji, Japan
Chiba, Japan
Gifu-shi, Japan
Matsumoto, Japan
Takatsuki, Japan
Funabashi, 2748555, Japan
Toki, Japan
Kanazawa, Japan
Izumo, 6938501, Japan
Okazaki, Japan
Kishiwada, Japan
Japan
Honjo, 8608556, Japan
Kitakyushu, 8078555, Japan
Hirakata, Japan
Higashiku, 8128582, Japan
Kurashiki, Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Phase 2 Basket Study of Tucatinib in Combination With Trastuzumab in Subjects With Previously Treated, Locally Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations
A Phase 2 Basket Study of Tucatinib in Combination With Trastuzumab in Subjects With Previously Treated, Locally Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations
Enrollment Status: Active_not_recruiting
Publish Date: August 21, 2026
Intervention Type: Drug
Study Drugs: Tucatinib, Trastuzumab, Fulvestrant
Study Phase: Phase 2
A Randomized Phase 3 Multicenter Open-Label Study to Compare the Efficacy of TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy in Patients With Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
A Randomized Phase 3 Multicenter Open-Label Study to Compare the Efficacy of TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy in Patients With Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
Enrollment Status: Active_not_recruiting
Publish Date: March 30, 2026
Intervention Type: Drug
Study Drugs: TAK-788, Pemetrexed, Cisplatin, Carboplatin
Study Phase: Phase 3
LIBRETTO-431: A Multicenter, Randomized, Open-Label, Phase 3 Trial Comparing Selpercatinib to Platinum-Based and Pemetrexed Therapy With or Without Pembrolizumab as Initial Treatment of Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer
LIBRETTO-431: A Multicenter, Randomized, Open-Label, Phase 3 Trial Comparing Selpercatinib to Platinum-Based and Pemetrexed Therapy With or Without Pembrolizumab as Initial Treatment of Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer
Enrollment Status: Active_not_recruiting
Publish Date: October 21, 2025
Intervention Type: Drug
Study Drugs: Selpercatinib, Carboplatin, Cisplatin, Pemetrexed, Pembrolizumab
Study Phase: Phase 3
An Adaptive Phase III, Multicenter, Randomized, Open-Label, Controlled Study of M7824 (Bintrafusp Alfa) Versus Pembrolizumab as a First-line Treatment in Patients With PD-L1 Expressing Advanced Non-small Cell Lung Cancer
An Adaptive Phase III, Multicenter, Randomized, Open-Label, Controlled Study of M7824 (Bintrafusp Alfa) Versus Pembrolizumab as a First-line Treatment in Patients With PD-L1 Expressing Advanced Non-small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: April 08, 2025
Intervention Type: Drug
Study Drugs: M7824, Pembrolizumab
Study Phase: Phase 3
A Multicenter, Double Blind, Randomized, Controlled Study of M7824 With Concurrent Chemoradiation Followed by M7824 Versus Concurrent Chemoradiation Plus Placebo Followed by Durvalumab in Participants With Unresectable Stage III Non-small Cell Lung Cancer
A Multicenter, Double Blind, Randomized, Controlled Study of M7824 With Concurrent Chemoradiation Followed by M7824 Versus Concurrent Chemoradiation Plus Placebo Followed by Durvalumab in Participants With Unresectable Stage III Non-small Cell Lung Cancer
Enrollment Status: Terminated
Publish Date: January 16, 2024
Intervention Type: Drug, Radiation
Study Drugs: M7824, Durvalumab, Etoposide, Pemetrexed, Carboplatin, Paclitaxel, Cisplatin
Study Phase: Phase 2
A Phase 1, Nonrandomized, Open-Label Investigation of Subcutaneous Ramucirumab Administration in Participants With Advanced Solid Tumors
A Phase 1, Nonrandomized, Open-Label Investigation of Subcutaneous Ramucirumab Administration in Participants With Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: February 27, 2023
Intervention Type: Drug
Study Phase: Phase 1
View 5 Less Clinical Trials

382 Total Publications

Bidirectional Regulation of c-Myc and TRB1 Establishes Oncogenic Reciprocal Regulation.
Bidirectional Regulation of c-Myc and TRB1 Establishes Oncogenic Reciprocal Regulation.
Journal: Biological & pharmaceutical bulletin
Published: August 30, 2026

Frequently Asked Questions about Hidetoshi Hayashi

Is Hidetoshi Hayashi a top-rated expert for Non-Small Cell Lung Cancer (NSCLC)?

MediFind is an objective health platform that identifies experts based on real-world data. Hidetoshi Hayashi is classified as an Elite expert for Non-Small Cell Lung Cancer (NSCLC), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Hidetoshi Hayashi participate in research or clinical trials?

Yes. Hidetoshi Hayashi has published 382 articles and abstracts on conditions like Non-Small Cell Lung Cancer (NSCLC). You can view a list of Hidetoshi Hayashi's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Hayashi's expertise for a condition
ConditionClose
View All 60 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile